TOKYO–(WORKING WIRE)–Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, later “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereafter “SEEDSUPPLY”) announces the start of joint research.
SEEDSUPPLY (https://www.seedsupply.co.jp/) proposes an agile drug discovery process for small molecules using selective binder technology as a self-assembly filter method. This technology can perform compound analysis of a protein or RNA, and then provide drug discovery results for various drug discovery targets, including those that make it difficult to measure biochemical activity. Additionally, a robust database developed for drug-identified classes will be used for selection, improving the efficiency and success of drug discovery processes. In addition, the database shows the possibility of wide use.
Elix (https://www.elix-inc.com/) is an AI drug discovery company with a mission of “Rethinking Drug Discovery.” To reduce cost and time while increasing the success of the drug discovery pipeline, Elix is looking at the use of machine learning in projects involving pharmaceutical companies, universities and research institutes. Elix has developed and released “Elix Discovery™,” the complete platform for AI drug discovery, offering everything from models for drug prediction and molecular design, to consulting and executive support in one group (https: //www.elix-inc.com/news/newsrelease/1620/). In addition to providing drug discovery support now, Elix is thinking about drug discovery in the future.
In this joint research project, SEEDSUPPLY will use Elix’s proprietary AI technology with the goal of significantly increasing the efficiency of screening processes. Elix will incorporate SEEDSUPPLY’s wealth of data, including its data on key drug discovery targets such as membrane proteins, into the AI training pipeline, thereby advancing the technology for. in silk techniques for screening compounds with better properties.
Elix and SEEDSUPPLY aim to leverage their strengths to reduce the cost and time of small molecule drug discovery and to address targets that are difficult to identify for conventional drug discovery methods.
Elix CEO Shinya Yuki’s comments
By combining the data obtained through SEEDSUPPLY’s proprietary technology and our proprietary AI models, we hope to see unique technological developments. We believe that this technology will enable people to analyze the most difficult targets at low cost in short periods of time, as well as to efficiently explore wide chemical areas.
Comments by SEEDSUPPLY CEO Naoki Tarui
The retention data of our company is the highest, because all content is measured using the same method. By teaming up with Elix’s advanced AI technology, we hope to create new innovations in AI drug discovery technology.